Jounce Therapeutics (JNCE) is Initiated by Robert W. Baird to “Outperform”

Jounce Therapeutics (JNCE) was Initiated by Robert W. Baird to “Outperform” and the brokerage firm has set the Price Target at $30. Robert W. Baird advised their Clients and Investors in a research report released on Feb 21, 2017.

Based on several research reports , JP Morgan Initiated Jounce Therapeutics on Feb 21, 2017 to “Overweight”, Price Target of the shares are set at $28.Jounce Therapeutics was Initiated by Wells Fargo to “Outperform” on Feb 21, 2017.

Jounce Therapeutics

Add Comment